Calquence (Acalabrutinib) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Calquence is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment, or adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Calquence is also referred to by its drug name, acalabrutinib.

Calquence is used as a targeted therapy for lymphoma. Calquence is a member of a class of drugs called tyrosine kinase inhibitors. Calquence is believed to work by blocking the growth of abnormal white blood cells, causing cell death.

How do I take it?
Prescribing information states that Calquence is given orally as a capsule approximately every 12 hours. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Calquence lists common side effects that include anemia (low red blood cell count), thrombocytopenia (low blood platelet count), neutropenia (low white blood cell count), headache, diarrhea, fatigue, muscle pain, and bruising.

Serious side effects listed for Calquence include hemorrhage (bleeding), infections, very low blood cell counts, and irregular heartbeat.

For more details about this treatment, visit:

Calquence — AstraZeneca

Acalabrutinib — Chemocare

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in